Autologous adipose-derived tissue stromal vascular fraction and intralesional epidermal growth factor combined application in patients with diabetic foot.
Aydın M., Akyüz S., Yanik H., Yildirim E., Başak AM., Güven HE.
Prospective Study with a reported sample of 11 on Diabetic Foot, Chronic Wound, published in J Wound Care (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- J Wound Care (2025)
- Country
- England
- Reported sample size
- 11
- Source database
- PubMed
- PMID
- 40056382
- DOI
- 10.12968/jowc.2024.0107
- Citations
- 1
Abstract (original English)
The aim of this study was to evaluate the effect on wound healing of intralesional epidermal growth factor (iEGF) (Heberprot-p; Hasbiotech, Cuba) and autologous adipose-derived tissue stromal vascular fraction (AD-tSVF) applied in the closure of tissue defects. The patients included in the study were separated into three approximately equal groups: Group 1 with iEGF+AD-tSVF applied; Group 2 with iEGF only applied; and Group 3 with conventional wound care products applied. Granulation tissue was taken from the wound bed before the application of iEGF and AD-tSVF and at intervals thereafter for flow cytometry analysis. Group 1 included 11 patients; Group 2 included 10 patients; and Group 3 included 10 patients. The time to re-epithelialisation was determined as 187.60±68.78 days in Group 3 patients compared with Group 1 (72.27±10.33 days) and Group 2 (70.50±18.02 days) (p<0.001). Following the application of iEGF to the wound bed, an increase was observed in M2 macrophage (CD209+), and M1 macrophage (CD38+) levels. The (CD34+) stem cells obtained from the granulation tissue after the application of AD-tSVF were determined to still be statistically significantly increased in the wound bed on the 21st day. The results of this study demonstrated that the application of iEGF and iEGF+ AD-tSVF significantly shortened the wound healing period compared with conventional methods. AD-tSVF
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisPubMed
Efficacy of Stem Cell-Derived Exosomes in Promoting Diabetic Foot Ulcer Healing: A Meta-Analysis of Preclinical Animal Studies.
Meta-analysis on Diabetic Foot, Chronic Wound, published in J Diabetes Res (2026) — summary generated from the PubMed abstract.
- 2026
J Diabetes Res - Level AMeta-analysisEurope PMC
Bone marrow-derived mesenchymal stem cells combined with intramuscular injection promote the healing of diabetic foot ulcers: a systematic review and meta-analysis
Meta-analysis with a reported sample of 2059 on Diabetic Foot, Chronic Wound, published in Front Endocrinol (Lausanne) (2026) — summary generated from the PubMed abstract.
- 2026
- n = 2059
Front Endocrinol (Lausanne) - Level AMeta-analysisEurope PMC
Comparative efficacy of advanced therapeutic modalities for diabetic foot ulcers: a systematic review and meta-analysis including NPWT, stem cells, ESWT, and bioengineered treatments
Meta-analysis on Diabetic Foot, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.
- 2026
Front Bioeng Biotechnol - Level AMeta-analysisPubMed
Therapeutic potential of adipose-derived stem cells for diabetic foot ulcers: a systematic review and meta-analysis.
Meta-analysis on Diabetic Foot, Chronic Wound, published in Diabetol Metab Syndr (2025) — summary generated from the PubMed abstract.
- 2025
Diabetol Metab Syndr6 citations - Level AMeta-analysisPubMed
A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus.
Meta-analysis on Diabetic Foot, Autoimmune Research, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
- 2025
Stem Cell Res Ther - Level AMeta-analysisEurope PMC
Comparison of the efficacy of 12 interventions in the treatment of diabetic foot ulcers: a network meta-analysis
Meta-analysis with a reported sample of 356 on Diabetic Foot, Chronic Wound, published in PeerJ (2025) — summary generated from the PubMed abstract.
- 2025
- n = 356
PeerJ1 citations